| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| Targets |
Natural biflavone; anti-inflammatory, anti-tumor, anti-oxidant, neuroprotective, anti-fungal activities
|
|---|---|
| ln Vitro |
Ginkgetin (2.5–20 μM; 48 hours) causes G2/M cell cycle arrest in Daoy cells and suppresses the growth of D283 and Daoy cell lines [2]. Osteosarcoma cells' apoptosis is markedly triggered by ginkgo (20–40 μM; 24 h) in a concentration-dependent manner [3]. In medulloblastoma cells, ginkgo (10–20 μM; 3–24 h) downregulates Wnt target gene expression without changing β-catenin expression [2]. In a concentration-dependent manner, ginkgo (1-10 μM) significantly inhibits the proliferation, migration, and wound recovery of endothelial cells induced by VEGF for 24 or 48 hours [1]. A549 cells die as a result of autophagy induced by ginkgo (5–10 μM; 48 hours) [5].
|
| ln Vivo |
Through the TLR4/NF-κB signaling pathway, ginkgo (25–100 mg/kg; intraperitoneally given two hours after ischemia) has anti-inflammatory effects on brain ischemia/reperfusion-induced damage in rat models [4]. ?In tumor-bearing nude mice, ginkgo (30 mg/kg; once daily gavage for 42 days) can prevent the formation of tumors in A549 cells [5].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: Daoy and D283 cell lines Tested Concentrations: 2.5, 5, 10, 20 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibited cell growth, the IC50 of Daoy and D283 cells were 14.65 and 15.81 μM respectively. Apoptosis analysis [3] Cell Types: Osteosarcoma cells Tested Concentrations: 20, 30, 40 μM Incubation Duration: 24 hrs (hours) Experimental Results: Dramatically induced osteosarcoma cell apoptosis in a concentration-dependent manner. Cell cycle analysis [2] Cell Types: Daoy cells Tested Concentrations: 2.5, 5, 10, 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Compared with the control, the G2/M phase increased, indicating G2/M cell phase arrest. Cell cycle analysis [2] Cell Types: Daoy and D283 cell lines Tested Concentrations: 10, 20 μM Incubation Duration: 3, 6, 12, 24 hrs (hours) Experimental Results: The expression of Wnt target genes, Axin2, cyclin D1 and survivin was attenuated at 20 μM. Daoy cells for 24 hrs (hours). Does not affect total beta-catenin levels and reduces beta-catenin phosphorylation levels in a time- and concentration-depen |
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (200-220 g) [4]
Doses: 25, 50, 100 mg/kg Route of Administration: intraperitoneal (ip) injection 2 hrs (hrs (hours)) after ischemia. Experimental Results: diminished neurological deficit score. Inhibits the expression of NF-κB, TLR4 and IκBα in the ischemic penumbra cortex, and inhibits the degradation of IκBα. Reduce the expression of ICAM-1, COX-2 and iNOS. Downregulates the expression of downstream inflammatory factors PGE2 and TNF-α. IL-1β, IL-6, IL-8, and IL-10 protein expression was diminished. |
| References |
|
| Additional Infomation |
Ginkgetin is a biflavonoid that is the 7,4'-dimethyl ether derivative of amentoflavone. Isolated from Ginkgo biloba and Dioon, it exhibits anti-HSV-1, antineoplastic and inhibitory activities towards arachidonate 5-lipoxygenase and cyclooxygenase 2. It has a role as an anti-HSV-1 agent, a cyclooxygenase 2 inhibitor, an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor, an antineoplastic agent and a metabolite. It is a biflavonoid, a hydroxyflavone, a methoxyflavone and a ring assembly. It is functionally related to an amentoflavone.
Ginkgetin has been reported in Selaginella sinensis, Taxus cuspidata, and other organisms with data available. |
| Molecular Formula |
C32H22O10
|
|---|---|
| Molecular Weight |
566.518
|
| Exact Mass |
566.121
|
| Elemental Analysis |
C, 67.84; H, 3.91; O, 28.24
|
| CAS # |
481-46-9
|
| PubChem CID |
5271805
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
863.7±65.0 °C at 760 mmHg
|
| Melting Point |
336ºC
|
| Flash Point |
287.2±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.714
|
| LogP |
4.45
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
42
|
| Complexity |
1080
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
AIFCFBUSLAEIBR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H22O10/c1-39-18-10-20(34)30-23(37)13-27(41-28(30)11-18)16-5-8-25(40-2)19(9-16)29-21(35)12-22(36)31-24(38)14-26(42-32(29)31)15-3-6-17(33)7-4-15/h3-14,33-36H,1-2H3
|
| Chemical Name |
5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxochromen-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)chromen-4-one
|
| Synonyms |
Ginkgetin; 481-46-9; 7,4'-Dimethylamentoflavone; Amentoflavone 7,4'-dimethyl ether; CHEBI:5353; HY5EZW8269; 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxochromen-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-(5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl)-2-(4-hydroxyphenyl)-;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 20.83 mg/mL (~36.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (3.53 mM) in 50% PEG300 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with heating and sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2 mg/mL (3.53 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication (<60°C). Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7652 mL | 8.8258 mL | 17.6516 mL | |
| 5 mM | 0.3530 mL | 1.7652 mL | 3.5303 mL | |
| 10 mM | 0.1765 mL | 0.8826 mL | 1.7652 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
